The Cigna Group (CI) investor relations material

Executive summary

• Q1 2026 revenues reached $68.5B, with adjusted EPS of $7.79, up 16% year-over-year, and net income rising 25% to $1.65B, driven by strong results in Evernorth and Cigna Healthcare.

• Adjusted income from operations increased 12% to $2.06B, with diluted EPS at $6.26, and shareholders' net income at $1.7B.

• Raised full-year 2026 adjusted EPS outlook to at least $30.35, reflecting confidence in sustained growth.

• Announced leadership transition: Brian Evanko to become CEO on July 1, with David Cordani moving to Executive Chair.

• Proactive portfolio reshaping includes exiting the individual exchange business after 2026 and initiating a strategic review of EviCore.

Financial highlights

• Q1 2026 revenues: $68.5B; adjusted EPS: $7.79 (16% year-over-year growth); adjusted income from operations: $2.06B (+12%).

• Evernorth revenues grew 9% to $58.4B; pre-tax adjusted earnings up 2% to $1.5B.

• Specialty and Care Services pre-tax adjusted earnings up 20% to $1.1B, driven by volume growth and biosimilar adoption.

• Pharmacy Benefit Services pre-tax adjusted earnings down 28% to $394M, reflecting client renewals and Signature model investments.

• Cigna Healthcare revenues: $11.5B; pre-tax adjusted earnings: $1.5B; medical care ratio (MCR): 79.8%.

Outlook and guidance

• Full-year 2026 adjusted EPS outlook raised to at least $30.35.

• Evernorth full-year 2026 adjusted income from operations expected at least $6.9B; Cigna Healthcare at least $4.525B.

• Second quarter adjusted EPS expected to be ~25% of full-year outlook; Q2 MCR to be slightly above full-year range due to seasonality.

• Cigna Healthcare Medical Care Ratio expected between 83.7% and 84.7% for 2026.

• Management expects continued growth in Evernorth and improved margins in Cigna Healthcare, with ongoing investments in client-focused initiatives and cost management.